Core Viewpoint - The company Haisheng Pharmaceutical (002099.SZ) has announced the initiation of Phase II clinical trials for its innovative therapeutic vaccine NWRD08, targeting HPV-related cervical lesions, marking a significant advancement in cancer treatment in China [1][2]. Group 1: Company Announcement - Haisheng Pharmaceutical received a notification from its subsidiary fund management company, Beijing Guoxin Zhongshu Investment Management Co., Ltd., regarding the participation of Guoxin Haisheng in the investment of Nuo Wei Biotechnology (Wuxi) Co., Ltd. [1] - The Phase II clinical trial for NWRD08 has officially started at several hospitals, including Peking Union Medical College Hospital, with the first subject enrolled and treated [1]. Group 2: Product Details - NWRD08 is the first therapeutic nucleic acid drug in China specifically designed for patients with HPV16/18 positive high-grade squamous intraepithelial lesions (HSIL), aiming to activate specific T-cell immunity to eliminate infected cells [2]. - Unlike preventive HPV vaccines, NWRD08 targets patients already infected with HPV and exhibiting related lesions, offering a new treatment approach [2]. - The Phase I clinical study demonstrated excellent safety and efficacy, with over 80% of subjects achieving either pathological downgrade or HPV virus clearance [2]. - NWRD08 provides a systemic immunotherapy option that is easy to administer and has a low recurrence rate, potentially protecting patients from cervical cancer and treating other HPV-related cancers such as anal, vulvar, and head and neck cancers [2].

Core Viewpoint - The company has announced the initiation of the Phase II clinical trial for NWRD08 injection, a therapeutic vaccine for HPV16/18 positive cervical high-grade squamous intraepithelial lesions (HSIL), marking a significant advancement in cancer treatment in China [1] Group 1: Company Developments - The company has received investment from Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) for its subsidiary, Nuo Wei Biotechnology (Wuxi) Co., Ltd [1] - The Phase II clinical trial for NWRD08 has officially started at Peking Union Medical College Hospital and several other hospitals, with the first subject enrolled and treated [1] Group 2: Product Details - NWRD08 injection is the first domestically developed therapeutic nucleic acid drug targeting HPV16/18 positive HSIL, designed to activate specific T-cell immunity to eliminate infected cells [1] - Unlike preventive HPV vaccines, NWRD08 specifically targets patients already infected with HPV and exhibiting related lesions, aiming to halt disease progression at its source [1] - The therapy allows female patients to retain their cervix compared to traditional surgical removal methods [1]

Core Viewpoint - Haishang Pharmaceutical (002099.SZ) announced that its investment partner, Guoxin Haishang, has participated in the clinical trial of the first on-demand therapeutic vaccine for cancer, NWRD08, developed by Nuowei Biotechnology, which has officially started in multiple hospitals including Peking Union Medical College Hospital [1] Group 1: Product Development - NWRD08 is China's first therapeutic nucleic acid drug targeting HPV16/18 positive high-grade squamous intraepithelial lesions (HSIL) that has entered Phase II clinical trials [1] - The drug activates specific T-cell immunity to eliminate infected cells, distinguishing it from preventive HPV vaccines, as it specifically targets patients already infected with HPV and exhibiting related lesions [1] Group 2: Treatment Advantages - NWRD08 aims to activate the body's specific CD8+ T-cell immune response to accurately identify and eliminate cells infected by HPV16/18, fundamentally preventing disease progression [1] - Compared to traditional surgical removal, this therapy allows female patients to retain their complete cervix [1]